De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

GlycoMimetics Beheer

Beheer criteriumcontroles 2/4

De CEO GlycoMimetics' is Harout Semerjian, benoemd in Aug2021, heeft een ambtstermijn van 3.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.39M, bestaande uit 26.7% salaris en 73.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.039% van de aandelen van het bedrijf, ter waarde $ 4.23K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 8.1 jaar.

Belangrijke informatie

Harout Semerjian

Algemeen directeur

US$2.4m

Totale compensatie

Percentage CEO-salaris	26.7%
Dienstverband CEO	3.2yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	8.1yrs

Recente managementupdates

Recent updates

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07

The Investment Case For GlycoMimetics

Nov 17

Analyse CEO-vergoeding

Hoe is Harout Semerjian's beloning veranderd ten opzichte van GlycoMimetics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$39m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$2m	US$638k	-US$37m
Sep 30 2023	n/a	n/a	-US$38m
Jun 30 2023	n/a	n/a	-US$37m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$1m	US$614k	-US$47m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$3m	US$244k	-US$63m

Compensatie versus markt: De totale vergoeding ($USD 2.39M ) Harout } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Harout is gestegen terwijl het bedrijf verliesgevend is.

CEO

Harout Semerjian (54 yo)

3.2yrs

Tenure

US$2,389,418

Compensatie

Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Harout Semerjian	CEO, President & Director	3.2yrs	US$2.39m	0.039% $ 3.9k
Rachel King	Co-Founder & Director	21.8yrs	US$96.00k	0.98% $ 97.8k
Brian Hahn	Senior VP & CFO	12.8yrs	US$1.30m	0.096% $ 9.6k
Edwin Rock	Senior VP & Chief Medical Officer	2.1yrs	US$1.15m	1.06% $ 104.8k
Stephanie Irish	Vice President of Accounting	5.8yrs	geen gegevens	geen gegevens
Christian Dinneen-Long	General Counsel & Company Secretary	5.5yrs	geen gegevens	geen gegevens
Bruce Johnson	Senior VP & Chief Commercial Officer	2.7yrs	geen gegevens	0.22% $ 21.4k
Chinmaya Rath	Senior VP & Chief Business Officer	1.7yrs	geen gegevens	0.25% $ 24.8k
Shantha Tyavanagimatt	Senior Vice President of Technical Operations	less than a year	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GLYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Harout Semerjian	CEO, President & Director	3.2yrs	US$2.39m	0.039% $ 3.9k
Rachel King	Co-Founder & Director	21.8yrs	US$96.00k	0.98% $ 97.8k
Daniel Junius	Independent Director	8.6yrs	US$118.50k	0.15% $ 15.2k
Timothy Pearson	Independent Chairman of the Board	10.6yrs	US$138.00k	0.038% $ 3.8k
Scott Koenig	Independent Director	7.6yrs	US$100.50k	0.057% $ 5.7k
Scott Jackson	Independent Director	5.9yrs	US$111.00k	0.0081% $ 808.3
Patricia S. Andrews	Independent Director	7.3yrs	US$105.00k	0.091% $ 9.0k
Mark A. Goldberg	Independent Director	10.3yrs	US$111.00k	geen gegevens

8.1yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GLYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).

GlycoMimetics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

Senior VP & Chief Medical Officer recently bought US$90k worth of stock

Chief Medical Officer recently bought US$248k worth of stock

Insider recently bought US$53k worth of stock

Insufficient new directors

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

Recent updates

Glycomimetics Announces to Reduce Its Workforce by Approximately 80%

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Receives Non-Compliance letter from Nasdaq Regarding Listing Rule 5450(a)(1)

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

New major risk - Financial position

New major risk - Revenue and earnings growth

New minor risk - Profitability

No longer forecast to breakeven

GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

New minor risk - Profitability

GlycoMimetics Can Become A Game Changer In Blood Cancers

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Price target decreased by 31% to US$5.50

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Senior VP & Chief Medical Officer recently bought US$90k worth of stock

GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

New minor risk - Market cap size

GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

No longer forecast to breakeven

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Price target decreased by 35% to US$5.50

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Chief Medical Officer recently bought US$248k worth of stock

GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Insider recently bought US$53k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

GlycoMimetics has a new Chief Medical Officer

Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021)

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$8.50

GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021)

Insufficient new directors

GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022

GlycoMimetics, Inc., Annual General Meeting, May 18, 2022

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Independent Director recently bought US$82k worth of stock

Price target increased to US$14.50

GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Price target increased to US$14.50

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index

Consensus forecasts updated

GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Senior VP of Clinical Development & Chief Medical Officer has left the company

Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML